前尿道狭窄疾病体外模型的验证与测试:评估磷酸二酯酶-4抑制与睾酮的潜在疗效
研究通过免疫组化在5例男性尸体尿道确认PDE4同工酶表达,并培养健康与狭窄尿道的成纤维细胞和上皮细胞,建立体外模型。TGFβ1以剂量依赖方式改变增殖和基因表达;roflumilast和睾酮维持细胞活力与增殖并降低狭窄相关基因表达,可能成为paclitaxel的非细胞毒性替代或补充。
要点
- PDE4-A、B、D沿尿道表达且区域间无差异
- 健康与狭窄尿道可培养成纤维细胞和上皮细胞用于体外研究
- PDE4抑制剂和睾酮维持细胞活力并降低aUSD相关基因表达
核心结论
- 尿道成纤维细胞和上皮细胞可从健康与狭窄手术标本培养,支持体外研究。
- PDE4抑制剂和睾酮可能作为aUSD的非细胞毒性替代或补充paclitaxel。
研究设计与样本
- 免疫组化在5例男性尸体尿道确认PDE4同工酶(A-D)存在与相对丰度。
- 从3例健康对照(阴道成形术患者尿道)和3例特发性球部尿道狭窄(L2S1E2,尿道成形术患者)培养人尿道成纤维细胞;上皮细胞来自1例健康对照和2例尿道狭窄。
- 对照成纤维细胞经TGFβ1刺激后与狭窄成纤维细胞比较增殖和aUSD相关基因表达;狭窄成纤维细胞经roflumilast、睾酮或paclitaxel处理并与对照比较。
主要发现
- PDE4-A、B、D沿尿道检测到且区域间无差异。
- TGFβ1以剂量依赖方式改变增殖和基因表达。
- roflumilast和睾酮维持细胞活力和增殖,并降低与aUSD正相关的基因表达。
临床怎么用
- 该体外模型可用于筛选aUSD的潜在药物治疗。
- PDE4抑制剂和睾酮值得进一步评估作为aUSD的非细胞毒性治疗选项。
局限性
- 样本量小(成纤维细胞每组n=3,上皮细胞来源有限)。
- 仅为体外研究,结论需临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To (1) determine the expression and distribution of all PDE4 isozymes (A-D) along the anterior urethra, (2) culture fibroblasts and epithelial cells from healthy and strictured urethras, (3) investigate an in vitro model of anterior urethral stricture disease (aUSD), and (4) assess the therapeutic potential of phosphodiesterase-4 (PDE4) inhibitors and testosterone compared to paclitaxel. METHODS: The presence and relative abundance of PDE4 isozymes (A-D) was confirmed using immunohistochemistry on 5 male cadaveric urethras. Human urethral fibroblasts (FBs) were cultured from healthy control urethras of patients undergoing vaginoplasty (n = 3) and from idiopathic bulbar urethral strictures (L2S1E2) of patients undergoing urethroplasty (n = 3). Epithelial cells (ECs) were cultured from a healthy control urethra and two urethral strictures. To investigate a model of aUSD, Control FBs were stimulated with TGFβ1 and compared to Stricture FBs on assays of cell proliferation and expression of genes relevant to aUSD pathophysiology. To test therapeutics, Stricture FBs were treated with the PDE4 inhibitor, roflumilast, testosterone (T), or paclitaxel and compared to Control FBs on the previously mentioned assays and cell viability. RESULTS: PDE4-A, B, and D were detected along the urethra and did not differ between regions. TGFβ1 altered proliferation and gene expression in a dose-dependent manner. Roflumilast and T preserved cell viability and proliferation and decreased expression of genes positively associated with aUSD. CONCLUSION: Urethral FBs and ECs can be cultured from healthy and strictured surgical specimens, enabling in vitro research. PDE4 inhibitors and T may be non-cytotoxic alternatives or additions to paclitaxel for aUSD.
引用
- Lozano LP, Volk MJ, Miller CD, et al. Validation and Testing of an In Vitro Model to Study Medical Treatments for Anterior Urethral Stricture Disease: Assessing the Potential Efficacy of Phosphodiesterase-4 Inhibition and Testosterone. Urology. 2026. PMID: 42562275. doi:10.1016/j.urology.2026.07.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。